European Archives - Page 45 of 1108 - European Medical Journal

Neurodegeneration and Cardiovascular Health: New Insights on Racial Differences

Better heart health cuts neurodegeneration biomarkers by 19% in the elderly, but racial disparities in CVH highlight need for targeted interventions.

AI-Driven Platform Predicts Outcomes in High-Risk Bladder Cancer

Notably, AI-driven models outperformed traditional clinical risk calculators like the EORTC and EAU models.

Apolipoprotein A-I Identified as Protective Factor in COPD

New research has identified a potential causal relationship between lipid metabolism and chronic obstructive pulmonary disease.

Probiotic Mixture Could Reduce Fever Duration in Children with URTIs

A recent study shows probiotics reduce fever duration by two days in children with URTIs, potentially providing a safe treatment option.

What is the Link Between Parkinson’s and Autism? ITSN1 Gene Reveals All

ITSN1 gene variant raises Parkinson’s risk tenfold, with links to autism. Breakthrough study reveals dual neurological threat.

5 minutes with... Prof Alexander Egeberg, LEO Pharma

Prof Alexander Egeberg, Vice President, Head of Global Medical Affairs, LEO Pharma, reveals how the company is tackling unmet needs in dermatology.

19 Mar 2025

Improving Management of Food Allergy

The symposium was held on the final day of the European Academy of Allergy and Clinical Immunology’s (EAACI) Food Allergy and Anaphylaxis…

Too Much TV? Heart Disease Risk Rises in Patients Prone to Type 2 Diabetes

People with a genetic risk for type 2 diabetes may face a greater threat to heart health if they spend too much time watching TV, according to a new study.

Sebastian Stintzing

Onc Now: Episode 13: Metastatic Colorectal Cancer Unravelled

Sebastian Stintzing, Head of Department of Medicine, Division of Hematology, Oncology, and Cancer Immunology, Charité – Universitäetsmedizin, Berlin, Germany, discusses the most impactful research into metastatic colorectal cancer.

Mast Cells, Interleukin-5, and Asthma Exacerbations Explained

Recent studies demonstrate that IL-5 treatment substantially increases type I and III IFN production in mast cells exposed to respiratory viruses.